European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

J. Alfred Witjes(Radboud University Nijmegen), Antoine G. van der Heijden(Radboud University Nijmegen), Y. Neuzillet(Université de Versailles Saint-Quentin-en-Yvelines), George N. Thalmann(University Hospital of Bern), Erik Veskimäe(Tampere University), Anja Lorch(University Hospital of Zurich), Richard Cathomas(Kantonsspital Graubünden), Éva Compérat(Vienna General Hospital), Nigel C. Cowan(Queen Alexandra Hospital), Virginia Hernández(Hospital Universitario Fundación Alcorcón), Georgios Gakis(University Hospital in Halle), Mathieu Rouanne(Université de Versailles Saint-Quentin-en-Yvelines), Harman Max Bruins(Zuyderland Medisch Centrum), María J. Ribal(Hospital Clínic de Barcelona)
European Urology
April 29, 2020
10.1016/j.eururo.2020.03.055
Cited by 2,166

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
|PubMed|1994|739
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694